Cargando…

Corrigendum to a new oral testosterone undecanoate (TU) therapy comes of age for the treatment of hypogonadal men

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381405/ https://www.ncbi.nlm.nih.gov/pubmed/34434258 http://dx.doi.org/10.1177/17562872211036391

Ejemplares similares

A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men
por: Swerdloff, Ronald S., et al.
Publicado: (2020)

Corrigendum for: “A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men”
Publicado: (2020)

Safety Analysis of an Oral Testosterone Undecanoate (TU) Formulation Following 2 Years of Administration in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2021)

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men
por: White, William B., et al.
Publicado: (2021)

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

SAT-044 Treatment of Hypogonadal Men with a New Oral Testosterone Undecanoate (TU) Formulation Improves Psychosexual, Well-Being and Body Composition and Bone Density Parameters
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

SUN-227 Monitoring Testosterone (T) Levels in Men Receiving Oral Testosterone Undecanoate (TU): Challenges Due to Post-Collection Conversion of TU-to-T and a Path Forward
por: Swerdloff, Ronald, et al.
Publicado: (2019)

Oral testosterone undecanoate is an effective treatment for micropenis therapy
por: Saenger, Paul, et al.
Publicado: (2021)

SAT-038 Ambulatory Blood Pressure Increases in Hypogonadal Men Who Develop Increases in Hematocrit on Oral Testosterone Undecanoate
por: Dobs, Adrian Sandra, et al.
Publicado: (2020)

SUN-234 Effect of Testosterone Undecanoate on Metabolic Syndrome Parameters in a Cohort of Hypogonadism
por: Yadav, Subhash Chandra, et al.
Publicado: (2019)

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

PMON267 Comparison Between Single Time Point Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Softgel (JATENZO®)
por: Swerdloff, Ronald, et al.
Publicado: (2022)

UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism
por: Bang, Anne Kirstine, et al.
Publicado: (2013)

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Saad, Farid, et al.
Publicado: (2019)

Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males
por: Pastuszak, Alexander W., et al.
Publicado: (2021)

OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

Effects of Five-Year Treatment with Testosterone Undecanoate on Metabolic and Hormonal Parameters in Ageing Men with Metabolic Syndrome
por: Francomano, Davide, et al.
Publicado: (2014)

Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy
por: Dimitriadis, Georgios K., et al.
Publicado: (2018)

Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials
por: Lachance, Sylvain, et al.
Publicado: (2015)

Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
por: Ide, Veerle, et al.
Publicado: (2020)

Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights
por: Campbell, Katherine, et al.
Publicado: (2023)

Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study
por: Chen, Yin-Wei, et al.
Publicado: (2019)

Testosterone Replacement Therapy and Bone Mineral Density in Men with Hypogonadism
por: Kim, Se Hwa
Publicado: (2014)

Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate
por: Zgair, Atheer, et al.
Publicado: (2021)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

Long-term testosterone replacement therapy reduces fatigue in men with hypogonadism
por: de Almeida Ferreira, Maurício, et al.
Publicado: (2022)

Comparative application of testosterone undecanoate and/or testosterone propionate in induction of benign prostatic hyperplasia in Wistar rats
por: An, Jinho, et al.
Publicado: (2022)

Anaphylaxis Triggered by Benzyl Benzoate in a Preparation of Depot Testosterone Undecanoate
por: Ong, Gregory S. Y., et al.
Publicado: (2012)

Testosterone Therapy for the Treatment of Age-Related Hypogonadism: Risks with Uncertain Benefits
por: Nguyen, Christine P., et al.
Publicado: (2021)

Recovery of Male Reproductive Endocrine Function Following Prolonged Injectable Testosterone Undecanoate Treatment
por: Shankara-Narayana, Nandini, et al.
Publicado: (2021)

Corrigendum to “Seminal plasma metabolomics signatures of normosmic congenital hypogonadotropic hypogonadism” [Heliyon 9(4) (March 2023) e14779]()
por: Li, Xiaogang, et al.
Publicado: (2023)

Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss
por: Yassin, AA, et al.
Publicado: (2013)

Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
por: Shoskes, Daniel A, et al.
Publicado: (2015)

Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis
por: Elliott, Jesse, et al.
Publicado: (2017)

Testosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol
por: Russo, Vittoria, et al.
Publicado: (2021)

ODP412 High Frequency of Erythrocytosis in Hypogonadal Men on Testosterone Replacement Therapy
por: Pérez-Luis, Jesús, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c143vh96lg2b7ducn0sgn5f57p